BioNxt Solutions Develops Sublingual Thin-Film for Semaglutide

BioNxt Solutions Inc. has announced the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, named BNT24005. Designed to improve patient accessibility and convenience, this product aims to address the limitations of current administration methods for Semaglutide, a drug developed by Novo Nordisk for Type 2 diabetes and obesity.

Semaglutide's existing injectable format poses challenges, including needle anxiety and adherence issues. BioNxt's thin-film technology offers a needle-free alternative, ensuring rapid absorption and improved bioavailability. This initiative aligns with patient-centric trends in healthcare, offering significant benefits to diabetes and obesity care.

The global prevalence of diabetes and obesity highlights the need for innovative treatments. BioNxt's strategic focus on enhancing drug delivery without infringing on existing patents aims to address these challenges, adhering to regulatory standards.